基本信息
浏览量:129
职业迁徙
个人简介
I have more than 37 years of experience as the PI of a laboratory studying the immune system’s response to malignancies. Throughout this period my lab’s long-term goal has been to manipulate an individual's immune response to reject cancer cells. In the 1990’s we were instrumental in demonstrating that CD4+ T helper lymphocytes are essential for immune-mediated tumor rejection. Recently, we were among the first labs to appreciate that myeloid-derived suppressor cells (MDSC) are highly immune suppressive cells present in virtually all cancer patients, and are a significant obstacle to active cancer immunotherapies. Our work demonstrating that MDSC are induced by a variety of pro-inflammatory mediators was described in a Science Magazine “News Focus” article and is the basis for the concept that chronic inflammation increases cancer risk and cancer progression by inducing MDSC which inhibit anti-tumor immunity. Our lab was also the first to demonstrate that macrophages, the other major pro-tumor myeloid cell population that infiltrates solid tumors, undergo cross-talk with MDSC which enhances the pro-tumor activity of both cell populations. Studies to date have identified a variety of physiological conditions and molecules that drive the accumulation and suppressive potency of MDSC and macrophages. However, neutralization of these cells has been unsuccessful because of the multiple pro-inflammatory mediators that drive their accumulation and function. Our preliminary studies, which are the basis for this application, demonstrate that the ubiquitously expressed alarmin, HMGB1, and the pro-inflammatory mediator S100A8/A9, are master regulators that activate MDSC by binding to the Receptor for Advanced Glycation Endproducts (RAGE). These observations led us to hypothesize that pro-tumor MDSC and TAMs may be neutralized by targeting RAGE, HMGB1, and S100A8/A9. If our hypothesis is correct, then our studies will provide a global and universal strategy for eliminating the suppressive activity of these myeloid cell populations and provide a more favorable environment for immunotherapy in cancer patients.
研究兴趣
论文共 215 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Katherine H. Parker,Pratima Sinha,Lucas A. Horn, Virginia K. Clements,Huan Yang,Jianhua Li,Kevin J. Tracey,Suzanne Ostrand-Rosenberg
crossref(2023)
Katherine H. Parker,Pratima Sinha,Lucas A. Horn, Virginia K. Clements,Huan Yang,Jianhua Li,Kevin J. Tracey,Suzanne Ostrand-Rosenberg
crossref(2023)
crossref(2023)
Katherine H. Parker,Pratima Sinha,Lucas A. Horn, Virginia K. Clements,Huan Yang,Jianhua Li,Kevin J. Tracey,Suzanne Ostrand-Rosenberg
crossref(2023)
Katherine H. Parker,Pratima Sinha,Lucas A. Horn, Virginia K. Clements,Huan Yang,Jianhua Li,Kevin J. Tracey,Suzanne Ostrand-Rosenberg
crossref(2023)
crossref(2023)
Katherine H. Parker,Pratima Sinha,Lucas A. Horn, Virginia K. Clements,Huan Yang,Jianhua Li,Kevin J. Tracey,Suzanne Ostrand-Rosenberg
crossref(2023)
Journal of immunology (Baltimore, Md. : 1950)no. 9 (2023): 1183-1197
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn